User login
Key clinical point: Patients with lung cancer have a high prevalence of frailty, which significantly increases the risk for mortality compared with nonfrail patients with lung cancer.
Major finding: The prevalence of frailty in patients with lung cancer was 45% (95% CI 28%-61%). Frailty vs. no frailty in patients with lung cancer was associated with a 3-fold higher mortality risk (hazard ratio 3.02; P < .001).
Study details: The data come from a meta-analysis of 16 studies including 4183 patients with lung cancer (mean age 65-80.75 years).
Disclosures: The study received no funding. L Bencivenga reported receiving research grants from multiple organizations. The other authors reported no conflicts of interest.
Source: Komici K et al. Frailty in patients with lung cancer: A systematic review and meta-analysis. Chest. 2022 (Feb 22). Doi: 10.1016/j.chest.2022.02.027
Key clinical point: Patients with lung cancer have a high prevalence of frailty, which significantly increases the risk for mortality compared with nonfrail patients with lung cancer.
Major finding: The prevalence of frailty in patients with lung cancer was 45% (95% CI 28%-61%). Frailty vs. no frailty in patients with lung cancer was associated with a 3-fold higher mortality risk (hazard ratio 3.02; P < .001).
Study details: The data come from a meta-analysis of 16 studies including 4183 patients with lung cancer (mean age 65-80.75 years).
Disclosures: The study received no funding. L Bencivenga reported receiving research grants from multiple organizations. The other authors reported no conflicts of interest.
Source: Komici K et al. Frailty in patients with lung cancer: A systematic review and meta-analysis. Chest. 2022 (Feb 22). Doi: 10.1016/j.chest.2022.02.027
Key clinical point: Patients with lung cancer have a high prevalence of frailty, which significantly increases the risk for mortality compared with nonfrail patients with lung cancer.
Major finding: The prevalence of frailty in patients with lung cancer was 45% (95% CI 28%-61%). Frailty vs. no frailty in patients with lung cancer was associated with a 3-fold higher mortality risk (hazard ratio 3.02; P < .001).
Study details: The data come from a meta-analysis of 16 studies including 4183 patients with lung cancer (mean age 65-80.75 years).
Disclosures: The study received no funding. L Bencivenga reported receiving research grants from multiple organizations. The other authors reported no conflicts of interest.
Source: Komici K et al. Frailty in patients with lung cancer: A systematic review and meta-analysis. Chest. 2022 (Feb 22). Doi: 10.1016/j.chest.2022.02.027